Collegium Expands ADHD Portfolio with $650M AZSTARYS Acquisition
Event summary
- Collegium Pharmaceutical to acquire AZSTARYS from Corium Therapeutics for $650M in cash, with up to $135M in potential milestone payments.
- AZSTARYS generated over 760,000 prescriptions in 2025 and is expected to contribute over $50M in pro forma net revenue in the second half of 2026.
- The acquisition is expected to close in Q2 2026, subject to regulatory approvals.
- Collegium will fund the acquisition using cash on hand and a $300M delayed draw term loan.
- AZSTARYS is supported by six Orange Book-listed patents, with most expiring in December 2037.
The big picture
Collegium's acquisition of AZSTARYS strengthens its position in the ADHD market, diversifying its commercial portfolio beyond responsible pain management. This strategic move aligns with Collegium's mission to build a leading, diversified biopharmaceutical company, leveraging its established ADHD commercial infrastructure to accelerate AZSTARYS' growth trajectory. The deal reflects a broader industry trend of consolidation in the neuropsychiatry space, as companies seek to expand their product offerings and extend revenue streams through strategic acquisitions.
What we're watching
- Integration Challenges
- How Collegium will integrate AZSTARYS into its existing ADHD portfolio and leverage its commercial infrastructure to drive growth.
- Financial Impact
- Whether the acquisition will meet Collegium's expectations of being immediately accretive to adjusted EBITDA and achieving annual run rate synergies of over $50M within twelve months post-closing.
- Market Positioning
- The pace at which Collegium can establish AZSTARYS as a leading treatment option for ADHD patients, competing with existing therapies.
Related topics